ELI-007 / Elicio Therap - LARVOL DELTA

AMP-peptide vaccination against mutant BRAF epitopes promotes lymph node delivery to generate potent, functional T cell immunity (AACR 2024) - P1 | "This approach was shown to promote activation of polyfunctional, cytotoxic T cells with promising safety, and improved clinical outcomes in a Phase 1 trial of ELI-002, an mKRAS AMP therapeutic vaccine (AMPLIFY-201 NCT04853017). These enhanced immune responses provide an encouraging therapeutic opportunity to treat >90% of BRAF-mutated cancers[5] with the AMP-mBRAF vaccine, ELI-007. Moreover, the AMP-platform technology is simple, rapidly executable, and scalable, promising broad clinical off-the-shelf application for BRAF."

IO biomarker • Oncology • BRAF • IFNG • IL2 • TNFA

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting (GlobeNewswire) - "Elicio Therapeutics...announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research ('AACR') Annual Meeting....Our preclinical program, ELI-007, is an investigational multivalent lymph node–targeted AMP peptide vaccine comprised of the V600E and V600K mutant antigens, developed to target BRAF gene mutations.....Lymph node-targeted AMP-vaccination resulted in a 19-fold increase in immune response after only 3 doses and a 42-fold increase after 5 doses when compared to conventional comparator vaccines....Substantial populations of mBRAF-specific T cells were found patrolling peripheral organs like the lung, which is one of the predominant sites for metastatic spread in melanoma and colorectal carcinoma."

Preclinical • Colorectal Cancer • Melanoma

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Elicio Therapeutics, Inc...announced three upcoming poster presentations at the American Association for Cancer Research ('AACR') Annual Meeting taking place from April 5-10, 2024, in San Diego, California. The presentations will highlight data on Elicio’s therapeutic cancer vaccine candidates, ELI-002, ELI-007 and ELI-008, built using Elicio’s Amphiphile ('AMP') technology, which harnesses the power of the lymph nodes to generate and activate T cells to target solid tumors."

Clinical data • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting (GlobeNewswire) - "The data will be presented at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023)....Both ELI-007 and ELI-008 have demonstrated strong induction of tumor-antigen-specific T cell responses in mice. Lymph node targeted AMP-vaccination resulted in T cell responses >10-500-fold increased over conventional comparators. Induced T cells were polyfunctional exhibiting production of multiple effector cytokines (IFNγ, TNFα, IL-2) and demonstrating cytotoxic killing in vivo alongside enhanced production of Granzyme B."

Preclinical • Oncology

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting (GlobeNewswire) - "Elicio Therapeutics...announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and ELI-008....These data will be presented in two poster presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) taking place at the San Diego Convention Center in San Diego, CA and virtually from November 1-5, 2023."

P1 data • Preclinical • Colorectal Cancer • Pancreatic Cancer

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines (GlobeNewswire) - "Elicio Therapeutics, Inc...today announced that it has been awarded a $2.6 million grant from the GI Research Foundation in Chicago to fund research for two therapeutic cancer vaccines, ELI-007 and ELI-008. This $2.6 million grant is an addition to the $2.8 million that it awarded Elicio in September 2022. Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations....This additional funding will help support the completion of all manufacturing, regulatory and clinical preparation needed to continue to move ELI-007 and ELI-008 forward. The grant will enable Elicio to pursue initial patient clinical assessment."

Financing • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Solid Tumor • Thoracic Cancer

The GastroIntestinal Research Foundation Launches New Multi-Million Dollar Funding Initiative Aimed at Curing Cancers of the Digestive System (PRNewswire) - "Elicio Therapeutics will use its GIRF funding on research for two therapeutic cancer vaccines. Both vaccines have been designed with Elicio's proprietary lymph node-targeting Amphiphile (AMP) platform that 'educates' T cells on how to target particular antigens, such as mutated proteins in cancer. ELI-007 is being developed to target the BRAF gene mutation, and ELI-008 is being developed to target hotspot mutations in p53 in solid tumors including colorectal cancer."

Commercial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines (GlobeNewswire) - "Elicio Therapeutics...announced that it has been awarded a $2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago to fund research for two therapeutic cancer vaccines.... ELI-007 is being developed to target the BRAF gene mutation, and ELI-008 is being developed to target hotspot mutations in p53 in solid tumors including colorectal cancer, melanoma and non-small cell lung cancer (NSCLC)."

Financing • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Solid Tumor